Ke Liu , MD, PhD

Dr. Ke Liu has over 30 years of experience in the medical and pharmaceutical industry. In 1990, they were a Visiting Scholar at the New York Blood Center. From 2001 to 2003, they were a Senior Clinical/Immunotherapy Fellow at the National Cancer Institute (NCI). During this time, they conducted translational research on cell and gene therapy for cancer, developed gene transfer protocols to lymphocytes, and was the protocol chairman for genetically modified tumor-infiltrating lymphocytes (TILs) clinical protocol in the treatment of cancer patients. In 2003, they joined the FDA as a Medical Officer and Clinical Reviewer in the Office of Cellular, Tissue and Gene Therapies (OCTGT). Ke Liu then progressed to Lead Medical Officer in the Office of Hematology and Oncology Products (OHOP) and Associate Director of Oncology Center of Excellence (OCE) in the Office of Cellular, Tissue and Gene Therapies (OCTGT). In 2020, they joined Sana Biotechnology, Inc. as Senior Vice President, Global Head of Regulatory Policy and Senior Vice President, Head of Regulatory Affairs & Strategy. Currently, they are the Chief Development Officer at Marengo Therapeutics.

Ke Liu, MD, PhD completed their Doctor of Medicine (M.D.) degree at Henan Medical University in Medicine. Ke Liu then obtained their Master's Degree in Microbiology and Immunology from the National Institute for the Control of Pharmaceutical and Biological Products (NICPBP) (Chinese FDA equivalent). Afterward, they obtained their Doctor of Philosophy (Ph.D.) in Molecular Biology from Cornell University Graduate School of Medical Sciences between 1991 and 1996. Ke Liu then completed their Internal Medicine Residency Program at Albert Einstein College of Medicine between 1996 and 1999, and obtained their ABIM --- Internal Medicine certification from the American Board of Internal Medicine in 1999. Finally, they completed their Medical Oncology Fellowship Training at the National Cancer Institute between 1999 and 2011, and obtained their Medical Oncology certification from the American Board of Internal Medicine in 2001.